| Abstract P057 – Table 1. Population characteristics at baseline and virologic failure over follow‐up among ART‐naïve PLWHIV | |||
|---|---|---|---|
| (N = 3810). | |||
| Baseline characteristics | DTG/3TC 2DR, N = 360 | BIC 3DR, N = 3114 | DTG 3DR,a N = 336 |
| Median age (IQR) | 30.7 (25.2 to 40.3) | 31.8 (26.2 to 41.5) | 34.1 (27.6 to 45.8) |
| Female, n (%) | 48 (13) | 444 (14) | 63 (19) |
| Black race, n (%) | 190 (53) | 1848 (59) | 214 (64) |
| Median viral load, log copies/mL (IQR) | 4.7 (4.2 to 5.2) | 4.8 (4.2 to 5.3) | 4.7 (4.0 to 5.2) |
| CD4 cell count <200 cells/μL, n (%) | 53 (15) | 763 (24) | 81 (24) |
| Comorbidities, n (%) | 140 (39) | 1221 (39) | 183 (54) |
| Confirmed virologic failureb | |||
| n (%) | 8 (2) | 97 (3) | 15 (5) |
| IR per 100 py (95% CI) | 1.74 (0.87 to 3.49) | 2.25 (1.85 to 2.75) | 3.55 (2.14 to 5.88) |
| Adjusted HRc,d (95% CI) | Ref | 1.12 (0.54 to 2.33) | 2.30 (0.94 to 5.60) |
| Months on regimen, median (IQR) | 15.0 (8.9 to 21.5) | 15.8 (11.0 to 23.2) | 14.6 (9.9 to 22.9) |
2DR, two‐drug regimen; 3DR, three‐drug regimen; 3TC, lamivudine; ABC, abacavir; BIC, bictegravir; DTG, dolutegravir; FTC, emtricitabine; HR, hazard ratio; IQR, interquartile range; IR, incidence rate; py, person‐years; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
aDTG 3DR includes DTG/ABC/3TC, DTG/TDF/FTC, and DTG/TAF/FTC;
bdefined as two consecutive viral loads ≥200 copies/mL after 24 weeks;
cmarginal structural model with inverse probability of treatment weights controlled for baseline age (quadratic), female, Black, Hispanic, Southern US, log10 viral load, CD4 cell count (quadratic);
d128 patients were excluded due to missing values (CD4).